Boston Scientific Corp. (BSX) — Analysis Summary
Boston Scientific Corp. (BSX) has a market cap of $67.64B with year-over-year revenue growth of +19.9%. Net margin stands at 14.4%. The stock trades at a P/E ratio of 18.4.
Key Takeaways
- Revenue changed +19.9% year-over-year
- Net margin of 14.4%
- P/E ratio of 18.4
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, BSX posted revenue growth of +19.9% and trades at a P/E of 18.4.
Boston Scientific Corp. (BSX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
59,000
Headquarters
MARLBOROUGH, MA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.